{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:14:55Z","timestamp":1780640095658,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100008383","name":"Stichting Parkinsonfonds","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008383","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Parkinsonismen Vereniging","award":["2012-V03 and 2013-R10"],"award-info":[{"award-number":["2012-V03 and 2013-R10"]}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["171102018"],"award-info":[{"award-number":["171102018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12883-015-0491-1","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T12:13:45Z","timestamp":1447935225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson\u2019s disease: the LEAP-study"],"prefix":"10.1186","volume":"15","author":[{"given":"Constant V. M.","family":"Verschuur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Suwijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dijkgraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"van Hilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tissingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M. A.","family":"de Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"issue":"23","key":"491_CR1","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","volume":"359","author":"PA Lewitt","year":"2008","unstructured":"Lewitt PA. Levodopa for the treatment of Parkinson\u2019s disease. N Engl J Med. 2008;359(23):2468\u201376.","journal-title":"N Engl J Med"},{"issue":"9949","key":"491_CR2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"PDMC Group","year":"2014","unstructured":"Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196\u2013205.","journal-title":"Lancet"},{"issue":"24","key":"491_CR3","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351(24):2498\u2013508.","journal-title":"N Engl J Med"},{"issue":"4","key":"491_CR4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21(4):343\u201354.","journal-title":"Arch Neurol"},{"issue":"15","key":"491_CR5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.0b013e318232ac0a","volume":"77","author":"CW Olanow","year":"2011","unstructured":"Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology. 2011;77(15):1416\u20137.","journal-title":"Neurology"},{"issue":"16","key":"491_CR6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383.","journal-title":"JAMA"},{"issue":"1","key":"491_CR7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6\u201323.","journal-title":"Neurotherapeutics"},{"key":"491_CR8","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson\u2019s disease rating scale. In: Fahn SMC, Calne DB, editors. Recent developments in Parkinson\u2019s disease, vol. Volume 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153\u201363. 293\u2013304."},{"issue":"23","key":"491_CR9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1212\/01.wnl.0000295666.30948.9d","volume":"69","author":"N Weisscher","year":"2007","unstructured":"Weisscher N, Post B, de Haan RJ, Glas CA, Speelman JD, Vermeulen M. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. Neurology. 2007;69(23):2155\u201361.","journal-title":"Neurology"},{"issue":"3","key":"491_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"491_CR11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mds.22921","volume":"25","author":"T Inoue","year":"2010","unstructured":"Inoue T, Kitagawa M, Tanaka T, Nakagawa S, Koyama T. Depression and major depressive disorder in patients with Parkinson\u2019s disease. Mov Disord. 2010;25(1):44\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"491_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.parkreldis.2007.05.005","volume":"14","author":"J Marinus","year":"2008","unstructured":"Marinus J, Visser M, Jenkinson C, Stiggelbout AM. Evaluation of the Dutch version of the Parkinson\u2019s Disease Questionnaire 39. Parkinsonism Relat Disord. 2008;14(1):24\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"491_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2000;69(1):67\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"491_CR14","volume-title":"Handleiding Short Form- Health and Labour Questionnaire (SF-HLQ)","author":"L Hakkaart-van Roijen","year":"2010","unstructured":"Hakkaart-van Roijen L, Bouwmans CAM. Handleiding Short Form- Health and Labour Questionnaire (SF-HLQ). Rotterdam: iMTA, Erasmus Universiteit; 2010."},{"issue":"3","key":"491_CR15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S0266462300009764","volume":"12","author":"L Roijen van","year":"1996","unstructured":"van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405\u201315.","journal-title":"Int J Technol Assess Health Care"},{"key":"491_CR16","volume-title":"iMTA Valuation of Informal Care Questionnaire (iVICQ). Version 1.0 (December 2011)","author":"RJ Hoefman","year":"2011","unstructured":"Hoefman RJ, van Exel NJA, Brouwer WBF. iMTA Valuation of Informal Care Questionnaire (iVICQ). Version 1.0 (December 2011). Rotterdam: iBMG \/ iMTA; 2011 [retrieved from www.bmg.eur.nl\/english\/imta\/ivicq\/documents\/ on 14\/10\/2015]."},{"key":"491_CR17","volume-title":"Handleiding Vragenlijst over Ziekte en Werk","author":"L Hakkaart-van Roijen","year":"1999","unstructured":"Hakkaart-van Roijen L, Essink Bot ML. Handleiding Vragenlijst over Ziekte en Werk. Rotterdam: Erasmus University\/ Institute for Medical Technology Assessment; 1999."},{"issue":"4","key":"491_CR18","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.socscimed.2005.06.046","volume":"62","author":"B Berg van den","year":"2006","unstructured":"van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835\u201345.","journal-title":"Soc Sci Med"},{"issue":"13","key":"491_CR19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med"},{"issue":"1","key":"491_CR20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson\u2019s disease rating scale. Arch Neurol. 2010;67(1):64\u201370.","journal-title":"Arch Neurol"},{"issue":"13","key":"491_CR21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMsm0904209","volume":"361","author":"RB D\u2019Agostino Sr","year":"2009","unstructured":"D\u2019Agostino Sr RB. The delayed-start study design. N Engl J Med. 2009;361(13):1304\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"491_CR22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.0b013e318281cc99","volume":"80","author":"DC Velseboer","year":"2013","unstructured":"Velseboer DC, Broeders M, Post B, van Geloven N, Speelman JD, Schmand B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80(7):627\u201333.","journal-title":"Neurology"},{"issue":"8","key":"491_CR23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.parkreldis.2010.06.003","volume":"16","author":"JC Sharma","year":"2010","unstructured":"Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16(8):490\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"491_CR24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord. 2013;28(8):1064\u201371.","journal-title":"Mov Disord"},{"issue":"Pt 10","key":"491_CR25","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731\u201342.","journal-title":"Brain"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0491-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T03:48:19Z","timestamp":1589600899000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2377\/15\/236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1186\/s12883-015-0491-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"article-number":"236"}}